ROIV vs. BBIO

In the year-to-date period, ROIV achieves a -10.06% return, which is significantly lower than BBIO's 24.53% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Roivant Sciences Ltd. (ROIV) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ROIV Sharpe Ratio is -0.18, which is lower than the BBIO Sharpe Ratio of 0.33. The chart below compares the historical Sharpe Ratios of ROIV and BBIO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ROIV nor BBIO has paid dividends to shareholders.

The maximum ROIV drawdown since its inception was -79.22%, smaller than the maximum BBIO drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for ROIV and BBIO. For additional features, visit the drawdowns tool.

The current volatility for Roivant Sciences Ltd. (ROIV) is 10.32%, while BridgeBio Pharma, Inc. (BBIO) has a volatility of 11.27%. This indicates that ROIV experiences smaller price fluctuations and is considered to be less risky than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Roivant Sciences Ltd. and BridgeBio Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.